Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17739921 | 1.00 | CASP2 (0.46) | CASP2NAAAL3MBTL1HPGDFAAH | |
| SCHEMBL19704124 | 0.91 | HPGD (0.35) | CASP2L3MBTL1HPGD | |
| SCHEMBL17739922 | 0.91 | HPGD (0.35) | CASP2L3MBTL1HPGD | |
| SCHEMBL19703938 | 0.90 | CASP2 (0.42) | CASP2NAAAL3MBTL1HPGDEPHX2 | |
| SCHEMBL17740143 | 0.90 | CASP2 (0.42) | CASP2NAAAL3MBTL1HPGDEPHX2 | |
| SCHEMBL17480080 | 0.88 | CA12 (0.34) | CASP2L3MBTL1HPGDEPHX2 | |
| SCHEMBL17740155 | 0.88 | CASP2 (0.53) | CASP2NAAAL3MBTL1HPGDFAAH | |
| SCHEMBL17740212 | 0.86 | L3MBTL1 (0.57) | CASP2NAAAL3MBTL1HPGDFAAH | |
| SCHEMBL19704337 | 0.86 | TSHR (0.33) | CASP2NAAAL3MBTL1 | |
| SCHEMBL19703734 | 0.86 | TSHR (0.33) | CASP2NAAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
| WO-2016071856-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS AG (CH) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | CASP2 2689/4885NAAA 1609/4885L3MBTL1 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.